BM-531

BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid -induced aggregation with an ED100 of 0.125 μM and U-46619 (HY-108566) -induced aggregation with an ED50 of 0.482 μM. BM-531 inhibits high-K+-induced contraction of porcine uterine smooth muscle[1][2][3].

Product Specifications

CAS Number

284464-46-6

UNSPSC

12352200

Hazard Statement

H302-H315-H319-H335

Target

Prostaglandin Receptor

Type

Biochemical Assay Reagents

Related Pathways

GPCR/G Protein

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/bm-531.html

Solubility

10 mM in DMSO

Smiles

O=S(C1=CC([N+]([O-])=O)=CC=C1NC2CCCCC2)(NC(NC(C)(C)C)=O)=O

Molecular Formula

C17H26N4O5S

Molecular Weight

398.48

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Dogné JM, et al. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids. 2000 May;62 (5) :311-7. |[2]Cao J, et al. Thromboxane A2 (TP) receptor in the non-pregnant porcine myometrium and its role in regulation of spontaneous contractile activity. Eur J Pharmacol. 2004 Feb 6;485 (1-3) :317-27. |[3]Michaux C, et al. N-tert-butyl-N'- (2-cyclohexylamino-5-nitrobenzenesulfonyl) urea, BM531, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition. Acta Crystallogr C. 2002 Oct;58 (Pt 10) :o621-3.